Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode

Radiation Oncology

Yoshihito Miyoshi²  Hiroya Ito²  Akihiro Hayashi¹  Chikao Sugie¹  Rumi Murata²  Yoshihiko Manabe²  Yuta Shibamoto¹  Taro Murai² 

[1] Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan;Department of Radiation Oncology, JA Suzuka General Hospital, Suzuka, Japan

关键词: Prostate cancer;    Lung cancer;    Intensity modulated radiotherapy;    TomoDirect;    Tomotherapy;   

Others  :  1154356
DOI  :  10.1186/1748-717X-8-68

 received in 2012-08-27, accepted in 2013-03-12,  发布年份 2013

【 摘 要 】

Purpose

With the new mode of Tomotherapy, irradiation can be delivered using static ports of the TomoDirect mode. The purpose of this study was to evaluate the characteristics of TomoDirect plans compared to conventional TomoHelical plans.

Methods

TomoDirect and TomoHelical plans were compared in 46 patients with a prostate, thoracic wall or lung tumor. The mean target dose was used as the prescription dose. The minimum coverage dose of 95% of the target (D95%), conformity index (CI), uniformity index (UI), dose distribution in organs at risk and treatment time were evaluated. For TomoDirect, 2 to 5 static ports were used depending on the tumor location.

Results

For the prostate target volume, TomoDirect plans could not reduce the rectal dose and required a longer treatment time than TomoHelical. For the thoracic wall target volume, the V5Gy of the lung or liver was lower in TomoDirect than in TomoHelical (p = 0.02). For the lung target volume, TomoDirect yielded higher CI (p = 0.009) but smaller V5Gy of the lung (p = 0.005) than TomoHelical. Treatment time did not differ significantly between the thoracic wall and lung plans.

Conclusion

Prostate cancers should be treated with the TomoHelical mode. Considering the risk of low-dose radiation to the lung, the TomoDirect mode could be an option for thoracic wall and lung tumors.

【 授权许可】

   
2013 Murai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Mackie TR: History of tootherapy. Phys Med Biol 2006, 51:R427-53.
• [2]Mackie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J: Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993, 20:1709-19.
• [3]Franco P, Catuzzo P, Cante D, La Porta MR, Sciacero P, Girelli G: TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori 2011, 97:498-502.
• [4]Reynders T, Tournel K, De Coninck P, Heymann S, Vinh-Hung V, Van Parijs H: Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments. Radiother Oncol 2009, 93:71-9.
• [5]Bhide SA, Nutting CM: Recent advances in radiotherapy. BMC Med 2010, 8:25. BioMed Central Full Text
• [6]Kissick MW, Mo X, McCall KC, Schubert LK, Westerly DC, Mackie TR: A phantom model demonstration of tomotherapy dose painting delivery, including managed respiratory motion without motion management. Phys Med Biol 2010, 55:2983-95.
• [7]Kissick MW, Flynn RT, Westerly DC, Hoban PW, Mo X, Soisson ET: On the impact of longitudinal breathing motion randomness for tomotherapy delivery. Phys Med Biol 2008, 53:4855-73.
• [8]Kanagaki B, Read PW, Molloy JA, Larner JM, Sheng K: A motion phantom study on helical tomotherapy: the dosimetric impacts of delivery technique and motion. Phys Med Biol 2007, 52:243-55.
• [9]Song CH, Pyo H, Moon SH, Kim TH, Kim DW, Cho KH: Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 2010, 78:651-8.
• [10]Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006, 65:640-5.
• [11]Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF: Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007, 69:350-7.
• [12]Kristensen CA, Nottrup TJ, Berthelsen AK, Kjaer-Kristoffersen F, Ravn J, Sorensen JB: Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009, 92:96-9.
• [13]Baba F, Shibamoto Y, Tomita N, Ikeya-Hashizume C, Oda K, Ayakawa S: Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol 2009, 4:15. BioMed Central Full Text
• [14]Shibamoto Y, Naruse A, Fukuma H, Ayakawa S, Sugie C, Tomita N: Influence of contrast materials on dose calculation in radiotherapy planning using computed tomography for tumors at various anatomical regions: a prospective study. Radiother Oncol 2007, 84:52-55.
• [15]Paddick I: A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 2000, 3(93):219-222.
• [16]Nakamura JL, Verhey LJ, Smith V, Petti PL, Lamborn KR, Larson DA: Dose conformity of gamma knife radiosurgery and risk factors for complications. Int J Radiat Oncol Biol Phys 2001, 51:1313-9.
• [17]Joseph KJ, Syme A, Small C, Warkentin H, Quon H, Ghosh S: A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancer. Radiother Oncol 2010, 94(1):60-6.
• [18]Edge SB, Byrd DR, Compton CC: American Joint Committee on Cancer. 7th edition. New York: Springer; 2010:457-468. [Prostate. AJCC Cancer Staging Manual]
• [19]Takemoto S, Shibamoto Y, Ayakawa S, Nagai A, Hayashi A, Ogino H: Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer. Radiat Oncol 2012, 7:87. BioMed Central Full Text
• [20]Davidson MT, Blake SJ, Batchelar DL, Cheung P, Mah K: Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:1550-8.
• [21]Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H: Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study. Technol Cancer Res Treat 2008, 7:441-7.
• [22]Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD: Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 2007, 32:166-71.
• [23]Bentzen SM, Trotti A: Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007, 25:4096-103.
• [24]Shibamoto Y, Jeremic B: Biologic premises of combined radiation therapy and chemotherapy in lung cancer. Hematol Oncol Clin N Am 2004, 18:29-40.
• [25]Vogelius IS, Westerly DC, Cannon GM, Mackie TR, Mehta MP, Sugie C: Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys 2011, 80:893-9.
• [26]Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS: Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S70-6.